Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin (ROLANDO)
Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube Cancer Patients.
Sponsor: AstraZeneca
Listed as NCT03161132, this PHASE2 trial focuses on Advanced Ovarian Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Apr 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Grupo Español de Investigación en Cáncer de Ovario
For direct contact, visit the study record on ClinicalTrials.gov .